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Abstract
Background: Insulin-like growth factor-1 (IGF-1), transforming growth factor β (TGFβ) and
cyclins are thought to play a role in myocardial hypertrophic response to insults. We investigated
these signaling pathways in canine models of ischemic or overpacing-induced cardiomyopathy.
Methods:  Echocardiographic recordings and myocardial sampling for measurements of gene
expressions of IGF-1, its receptor (IGF-1R), TGFβ and of cyclins A, B, D1, D2, D3 and E, were
obtained in 8 dogs with a healed myocardial infarction, 8 dogs after 7 weeks of overpacing and in
7 healthy control dogs.
Results:  Ischemic cardiomyopathy was characterized by moderate left ventricular systolic
dysfunction and eccentric hypertrophy, with increased expressions of IGF-1, IGF-1R and cyclins B,
D1, D3 and E. Tachycardiomyopathy was characterized by severe left ventricular systolic
dysfunction and dilation with no identifiable hypertrophic response. In the latter model, only IGF-
1 was overexpressed while IGF-1R, cyclins B, D1, D3 and E stayed unchanged as compared to
controls. The expressions of TGFβ, cyclins A and D2 were comparable in the 3 groups. The
expression of IGF-1R was correlated with the thickness of the interventricular septum, in systole
and diastole, and to cyclins B, D1, D3 and E expression.
Conclusion: These results agree with the notion that IGF-1/IGF-1R and cyclins are involved in the
hypertrophic response observed in cardiomyopathies.
Background
Insulin-like growth factor-1 (IGF-1) is thought to be
involved in cardiac tissue maintenance and function.
Interaction of IGF-1 with its receptor (IGF-1R) stimulates
DNA and protein syntheses [1], contractility [2] and
inhibits apoptosis [3] in cardiac myocytes through an
autocrine pathway [4]. This signaling pathway also partic-
ipates in post-ischemic neovascularisation, promoting
multiplication of endothelial cells and formation of
endothelial tubes[5].
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Transforming growth factor β (TGFβ) participates in the
cardiac remodeling process including cardiac fibrosis and
modulation of cardiac myocytes hypertrophy. In vitro,
TGFβ induces the production of extracellular matrix com-
ponents, stimulates fibroblast proliferation and its con-
version to myofibroblast [6]. In vivo, TGFβ is correlated
with the degree of fibrosis [7]. The involvement of the
TGFβ-activated kinase 1 pathway induces cardiac hyper-
trophy while the Smad-dependent pathway may inhibit
cardiac myocytes hypertrophy [8].
Whether cardiac myocytes might retain the capability to
proliferate has remained unsettled until the very recent
report of a 1-0.5% yearly rate of replacement of cardiac
muscle cells in human adults [9]. In the adult heart, the
majority of myocytes are blocked in the G0 or G1 phases
of the cell cycle, consistent with terminal differentiation
of these cells. However, in vitro studies have shown that
the interaction of IGF-1 with its IGF-1R receptor may stim-
ulate the re-entry of adult ventricular myocytes into the
cell cycle [10]. These cells therefore proceed through G1 to
synthesize the necessary mRNA and proteins for hyper-
trophic growth and some will enter the S phase and
undergo DNA synthesis and binucleation [11] and proba-
bly also mitosis in a proportion of them. Cell cycle pro-
gression is controlled by regulatory molecules called
cyclins [12].
Different types of cardiomyopathies are associated with
variable hypertrophic and perhaps hyperplasic responses,
and these can be reproduced experimentally. We previ-
ously reported canine models of overpacing-induced
dilated cardiomyopathy with no detectable hypertrophy
[13] and of ischemic cardiomyopathy on a healed small
size myocardial infarction with a marked hypertrophic
reaction [14]. We therefore investigated the gene expres-
sions of IGF-1 and cyclins in these two models of cardiac
disease.
Methods
All the investigation protocols had been approved by the
Institutional Animal Care and Use Committee of the Uni-
versité Libre de Bruxelles and were conducted in accord-
ance with the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health
(NIH Publication No. 85-23. Revised 1996).
Echocardiographic recordings and myocardial tissue spec-
imens were obtained from 8 beagle dogs 28 weeks after a
myocardial infarction, 8 beagle dogs after 7 weeks of over-
pacing and 7 healthy control dogs.
Cardiomyopathy secondary to healed myocardial 
infarction
Briefly, under general anesthesia, a left thoracotomy was
performed to ligate directly the left circumflex artery and/
or its marginales, as previously described [14]. An
echocardiographic examination was performed at base-
line and 28 weeks after recovery. The animals were then
killed by an overdose of anesthetics, and myocardial tis-
sue sampled from the infarcted and border zones situated
in the left ventricular free wall and from a remote zone sit-
uated in the interventricular septum. The tissue samples
were snap frozen in liquid nitrogen and stored at -80°C
until use.
Overpacing-induced dilated cardiomyopathy
Briefly, under general anesthesia, a transvenous pace-
maker lead was inserted in the right ventricular apex and
connected to a pacemaker inserted subcutaneously in the
cervical region, as previously described [13]. After a 2-
week recovery, the dogs underwent a modified pacing
protocol with stepwise increases in stimulation frequency.
The pacing was initiated at a rate of 180 beats per minute
for one week, followed by a rate of 200 beats per minute
during a second week, 220 beats per minute during a third
week and finally 240 beats per minute from week 4 to
week 7. Echocardiography was performed at baseline
(before activation of the pacemaker) and at week 7. The
animals were then killed by an overdose of anesthetics,
and myocardial tissue sampled from the left ventricular
free wall and from the interventricular septum. The sam-
ples were snap frozen in liquid nitrogen and stored at -
80°C until use.
Control dogs
Myocardial tissue of the left ventricular free wall and of
the interventricular septum were harvested from 7 normal
beagle dogs killed with an overdose of anesthetics.
Echocardiography
Echocardiography (Vivid 5, GE, Brussels, Belgium or Pan-
dion, Pie Medical Benelux, Zaventem, Belgium) was car-
ried out under continuous ECG monitoring with a 5 MHZ
electronic probe, the dog lying in lateral recumbency
being scanned through the dependent chest wall [15]. A
bidimensional guided M-mode right short axis view of the
left ventricle at the level of the chordae tendinae was
recorded. From these recordings, we measured end-
diastolic and end-systolic left ventricular diameters (LVDd
and LVDs), interventricular septum thickness (IVSd and
IVSs) and left ventricular free wall thickness (LVFWd and
LVFWs). Left ventricular end-diastolic and end-systolic
volumes (LVEDV and LVESV), fractional shorthening
(FS), ejection fraction (LVEF), interventricular septum
and left ventricular free wall fractional thickening (IVSFT
and LVFWFT), relative wall thickness (RWT) and left ven-BMC Cardiovascular Disorders 2009, 9:49 http://www.biomedcentral.com/1471-2261/9/49
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tricular mass (LVmass) were calculated using formulas
shown on listed in table 1. The mean value of 3 measure-
ments of the technically best cardiac, cycles irrespective of
the respiratory phase, was taken. All images were analyzed
according to the recommendations of the American Soci-
ety of Echocardiography [16] and the Echocardiography
Committee of the Specialty of Cardiology, American Col-
lege of Veterinary Internal Medicine [17].
Quantitative real time polymerase chain reaction (QRT-
PCR)
Total RNA was extracted using the Trizol method (Invitro-
gen, Merelbeke, Belgium)., After first strand cDNA synthe-
sis, Sybr Green RTQ-PCR was performed (Icycler, Biorad
Laboratory, Nazareth, Belgium). For each gene, the PCR
conditions were optimized to obtain only the specific
product with an efficiency calculated from dilution curves
(7×) between 95 and 105%. Each sample was measured in
triplicate and each plate contained negative and positive
controls. Abbelson (ABL) was used as a housekeeping
gene. Statistical analysis was carried out using the differ-
ences between the cycles threshold (Ct) (ΔCt = Ct gene of
interest - Ct housekeeping gene). Relative gene expression
values were obtained using the ΔΔCt method (ΔCt sample
- ΔCt calibrator) using control (CTRL) as calibrator. The
conversion of ΔΔCt to relative gene expression is Fold
induction: 2-ΔΔCt [18].
Statistical analysis
All results are expressed as mean ± SEM and statistical sig-
nificance is determined at p < 0.05. Distribution normal-
ity was tested with a Kolmogorov-Smirnov test.
Echocardiographic data were compared by paired t-tests.
For QRT-PCR data, normally distributed data were tested
by a one-way ANOVA, followed by Scheffé post-hoc tests
when overall significance was detected. When the Kol-
mogorov-Smirnov test failed, differences between groups
were tested by a Kruskal-Wallis test. Coefficients of
weighted linear regression (R) and associated probabili-
ties (P) were determined to examine the relationship
between relative cardiac IGF-1R mRNA expression (x-axis)
and the interventricular septum thickness or relative car-
diac cyclins expression (y-axis) [19].
Results
Echocardiography
Table 2 summarizes the echocardiographic measurements
in the dogs with ischemic cardiomyopathy and tachycar-
diomyopathy respectively, at baseline and before eutha-
nasia.
The dogs with ischemic cardiomyopathy had increased
LVEDV, IVSd and LVmass and unchanged RWT, indicating
eccentric hypertrophy. The LVEF was decreased but
remained above 50%, The FS was mildly reduced but
remained above 25% while IVSFT and LVFWFT were also
reduced and LVESV was increased, indicating moderate
global systolic dysfunction. The dogs with tachycardiomy-
opathy had increased LVEDV with decreased IVSd, LVFWd
and RWT and no change in LVmass indicating LV dilation
without hypertrophy. The LVEF, FS, IVSFT and LVFWFT
were markedly reduced and LVESV markedly increased,
suggesting severe global systolic dysfunction.
QRT-PCR
In control dogs, the expressions of IGF-1, IGF-1R, TGFβ
and cyclins A, B, D1, D2, D3 and E were not different in
the left ventricular free wall from those in the interven-
tricular septum. Therefore, in comparisons, we used the
mean of the ΔCt obtained in the 2 localisations. The
expression of IGF-1 was increased in the remote, border
and infarction zones in dogs with ischemic cardiomyopa-
thy, and also increased in the myocardium of dogs with
tachycardiomyopathy (Figure 1a). On the other hand, the
expression of IGF-1R was increased in the 3 infarction
zones of the dogs with ischemic cardiomyopathy, but not
in the myocardium of dogs with tachycardiomyopathy
(Figure 1b). In the dogs with ischemic cardiomyopathy
but not in those with tachycardiomyopathy, there were
increased expressions of cyclins B, D1, D3 and E (Figure
Table 1: Formulas which were used for calculating echocardiographic indices
Echocardiographic indices Formulas
LVEDV (LVDd3 × 7)/(2.4 + LVDd
LVESV (LVDs3 × 7)/(2.4 + LVDs)
LVEF ((EDV-ESV)/EDV) × 100
FS {(LVDd -- LVDs)/LVDd} × 100
IVSFT {(IVSs -- IVSd)/IVSd} × 100
LVFWFT {(LVFWs -- LVFWd)/LVFWd} × 100
RWT 2 × (IVSd/LVDd)
LV mass 1.04 × {(LVDd + IVSd + LVFWd)3 - LVDd3}
LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVEF, left ventricular ejection fraction; FS, fractional 
shortening; IVSFT, interventricular septum fractional thickening; LVFWFT, left ventricular free wall fractional thickening; RWT, relative wall 
thickness; LVmass, left ventricular massBMC Cardiovascular Disorders 2009, 9:49 http://www.biomedcentral.com/1471-2261/9/49
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2). The expressions of TGFβ, cyclin A and D2 remained
unchanged in both models (data not shown). There were
significant correlations between relative gene expression
of IGF-1R and the echocardiographic variables IVSd and
IVSs (Figure 3) as well as between IGF-1R and cyclin B,
D1, D3 and E (Figure 4).
Discussion
The present results show that the expression of IGF-1 is
increased in 2 models of cardiomyopathy with markedly
different hypertrophic responses. However, the expres-
sion of its receptor IGF-1R was increased in post myocar-
dial infarction hypertrophic cardiomyopathy only.
Furthermore, the expression of IGF-1R was related to the
Table 2: Echocardiographic data in postischemic and overpacing models
Infarct Paced
Echocardiographic indices Baseline End Baseline End
LVEF,% 68 ± 3 55.5 ± 3 § 66 ± 2 35 ± 2 *
FS, % 37 ± 2 33 ± 1 36 ± 1 17 ± 1 *
LV mass, g 92 ± 4 118 ± 8 ‡ 126 ± 7 127 ± 6
IVSd, mm 7.1 ± 0.2 8 ± 0.3 7 ± 0.2 6 ± 0.3 §
IVSs, mm 11.2 ± 0.4 12 ± 0.8 11 ± 0.6 6 ± 0.3 *
LVDd, mm 36.5 ± 0.5 42 ± 2 § 39 ± 1.5 50 ± 2 *
LVDs, mm 23 ± 1 28 ± 1 § 25 ± 1 41 ± 1 *
LVFWd, mm 8 ± 0.3 7.2 ± 0.5 7.8 ± 0.4 6.5 ± 0.3 ‡
LVFWs, mm 12 ± 0.3 10 ± 0.7 ‡ 12 ± 0.5 9.6 ± 0.4 §
RWT 0.4 ± 0.02 0.4 ± 0.02 0.4 ± 0.02 0.2 ± 0.02 *
LVEDV, ml 56 ± 2 81 ± 8 § 66 ± 6 117 ± 9 *
LVESV, ml 18 ± 2 32 ± 4 § 22 ± 2 76 ± 6 *
IVSFT, % 58 ± 7 48 ± 6 49 ± 9 14 ± 4 §
LVFWFT, % 53 ± 4 40 ± 5 ‡ 56 ± 3 40 ± 5 ‡
LVEF, left ventricular ejection fraction; FS, fractional shortening; LVmass, left ventriular mass; IVSd, interventricular septum thickness in diastole; 
IVSs, interventricular septum thickness in systole; LVDd, left ventricular diameter in diastole; LVDs, left ventricular diameter in systole; LVPWd, left 
ventricular posterior wall diameter in diastole; LVPWs, left ventricular posterior wall diameter in systole; RWT, relative wall thickness; LVEDV, left 
ventricular end diastolic volume; LVESV, left ventricular end systolic volume; IVSFT, interventricular septum fractional thickening; LVFWFT, left 
ventricular free wall fractional thickening. ‡ p < 0.05, § p < 0.01, * p < 0.001 in each end group versus baseline.
Relative gene expression of IGF-1 (A) and IGF-1R (B) in control dogs (CTRL) vs infarcted dogs in 3 myocardial zones (MR =  remote zone, MB = border zone and MI = infarct zone) and paced dogs Figure 1
Relative gene expression of IGF-1 (A) and IGF-1R (B) in control dogs (CTRL) vs infarcted dogs in 3 myocardial 
zones (MR = remote zone, MB = border zone and MI = infarct zone) and paced dogs.
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expression of cell cycle regulatory molecules cyclins B, D1,
D3 and E, and with echocardiographic measures of myo-
cardial hypertrophy. Therefore, these data are in keeping
with the notion of a positive interaction between IGF-1
and cyclin signaling systems in the myocardial hyper-
trophic responses to insults.
The expression of IGF-1 has been shown to be increased
in a variety of cardiac conditions [1], including acromeg-
alic cardiomyopathy [20], chronically increased afterload
[1,21] or volume overload [22] and acute myocardial inf-
arction [4,23]. The present results add different models of
chronic heart failure to this list. Thus increased gene
expression of IGF-1 appears to be a universal and non-spe-
Relative gene expression of Cyclin B (A), Cyclin D1 (B), Cyclin D3 (C) and Cyclin D3 (D) in control dogs (CTRL) vs infarcted  dogs in 3 myocardial zones (MR = remote zone, MB = border zone and MI = infarct zone) and paced dogs Figure 2
Relative gene expression of Cyclin B (A), Cyclin D1 (B), Cyclin D3 (C) and Cyclin D3 (D) in control dogs 
(CTRL) vs infarcted dogs in 3 myocardial zones (MR = remote zone, MB = border zone and MI = infarct zone) 
and paced dogs.
Cyclin B
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00
CTRL MR MB MI Paced
R
e
l
a
t
i
v
e
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
**
**
**
Cyclin D1
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
CTRL MR MB MI Paced
R
e
l
a
t
i
v
e
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
**
**
***
Cyclin D3
0.00
0.50
1.00
1.50
2.00
2.50
3.00
CTRL MR MB MI Paced
R
e
l
a
t
i
v
e
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
*
*
Cyclin E
0.00
0.50
1.00
1.50
2.00
2.50
3.00
CTRL MR MB MI Paced
R
e
l
a
t
i
v
e
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
***
***
(a) (b)
(c) (d)BMC Cardiovascular Disorders 2009, 9:49 http://www.biomedcentral.com/1471-2261/9/49
Page 6 of 9
(page number not for citation purposes)
cific response of myocardial tissue to injury. The expres-
sion of IGF-1R has been shown to be increased in the left
ventricle of rats with hypertrophic cardiomyopathy sec-
ondary to norepinephrine infusion [24] and also in acute
myocardial infarction [4,23,25]. Furthermore, the expres-
sion of IGF-1R has been shown to decrease with ageing in
the male rat heart and associated with cardiac decompen-
sation [26]. A decreased activation of cardiomyocyte IGF-
1R by IGF-1 has been reported in a model of alcoholic car-
diomyopathy and this was associated with an absence of
protein synthesis after IGF-1 incubation [27]. In the
present study, there was an increased expression of IGF-1R
in ischemic cardiomyopathy but not in tachycardiomyop-
athy, indirectly suggesting that parallel increased expres-
sions of IGF-1 and its receptor are only to be observed in
myocardial injury with a hypertrophic response.
Recent report of a physiological 1-0.5% turnover in adult
human cardiomyocytes [9] has reactivated the question
whether myocardiac hypertrophic responses might be
associated with a proliferative reaction like tissue repair.
We therefore wondered about possible interactions
between IGF-1 signaling and the expression of cyclins,
which are regulatory molecules controlling cell cycle pro-
gression [12]. Cyclins D and E regulate the synthesis of
mRNA and proteins necessary for DNA synthesis and tran-
sition from the first gap G1 phase to the G1-S phase that
precedes the progression to the second gap G2 phase dur-
ing which additional mRNA and protein are synthesized
in preparation to cell division (G2-M phase). Cyclin A is
involved in the progression through the G1-S phase, and
cyclin B promotes transition from the the G2 phase into
mitosis [12].
In vitro, IGF-1R and its ligand regulate the re-entry of
adult ventricular myocytes into the cell cycle [10]. On the
other hand, cardiac myocytes proliferation slows down
and ceases early during postnatal development [28] and
this attenuation is paralleled by a downregulation of the
myocardial IGF-1 system [29]. Fetal cardiomyocytes
express high levels of cyclins both at mRNA and protein
levels but shortly after birth, their expression profile
becomes progressively downregulated [30]. However, the
adult heart retains the ability to undergo cyclin modula-
tion-associated DNA synthesis following hemodynamic
overload or injury [11]. In a model of pressure overload-
induced left ventricular hypertrophy, a transient upregula-
tion of cyclins D2 and D3 was observed during the com-
pensated hypertrophic stage [31]. Acute myocardial
infarction is also coupled with an activation of cardiac cyc-
lins [32]. In this study, we show that the gene expressions
of cyclins B, D1, D3 and E are increased in ischemic cardi-
omyopathy in relation to increased IGF-1 and IGF-1R
expressions and echocardiographic measures of wall
thickness but are not increased in tachycardiomyopathy.
It is to be noted that the expression of cyclin D2 did not
vary in either model, which finding is at variance with a
previous report [31]. Our data do not offer an explanation
for this apparent discrepancy. We speculate that there may
be differential expression of various D-type cyclins
Scatterplots of IGF-1R relative gene expression on x-axis versus IVSd (interventricular septum thickness in diastole) Figure 3
Scatterplots of IGF-1R relative gene expression on x-axis versus IVSd (interventricular septum thickness in 
diastole). (A) and IVSs (interventricular septum thickness in systole) (B) on y-axis in control dogs (CTRL), infarcted dogs 
(mean expression of the 3 zones) and paced dogs.
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Scatterplots of IGF-1R relative gene expression (x-axis) versus Cyclin B relative gene expression (A), Cyclin D1 relative gene  expression (B), Cyclin D3 relative gene expression (C) and Cyclin E relative gene expression (D) (y-axis) in control dogs  (CTRL), infarcted dogs (mean of the 3 zones) and paced dogs Figure 4
Scatterplots of IGF-1R relative gene expression (x-axis) versus Cyclin B relative gene expression (A), Cyclin 
D1 relative gene expression (B), Cyclin D3 relative gene expression (C) and Cyclin E relative gene expression 
(D) (y-axis) in control dogs (CTRL), infarcted dogs (mean of the 3 zones) and paced dogs.
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depending on the type of normal or pathologic cells
[33,34], and also time-, disease- and species-related differ-
ences, not to mention D-type cyclin redundancies [35].
The observation that an infarct regression has been seen in
mice overexpressing cyclin D2, but not in mice overex-
pressing cyclin D1 or cyclin D3 makes D-type cyclin
redundancies less likely [35]. The molecular nature of the
interactions between IGF-1 and cyclins and whether this
implies a potential for tissue regeneration through cardiac
myocyte proliferation in addition to hypertrophy remain
unresolved issues.
In the present study, the gene expression of TGFβ was
unchanged in the 2 types of cardiomyopathies as com-
pared to the controls. The overexpression of TGFβ in
transgenic mice results in cardiac hypertrophy which is
characterized by both interstitial fibrosis and hyper-
trophic growth of cardiac myocytes [36]. The expression
of TGFβ has been previously shown to be increased in ani-
mal models of cardiac pressure overload and infarction
[37,38]. The absence of a significant increase in the
expression of TGFβ in our dogs with ischemic cardiomy-
opathy may be related to small numbers of animals (type
II error) or to different stages of the disease from those
previously reported. An important limitation of the
present findings is the absence of protein measurements
related to mRNA content measurements. We were unable
to find satisfactory antibodies enabling these measure-
ments to be made in canine myocardial tissue. Another
limitation is the absence of functional evaluations.
Conclusion
Taken together, these results support the notion that mod-
ulation of the expression of IGF-R1 and cyclins B, D1, D3
and E genes are involved in the various hypertrophic
response observed in cardiomyopathies.
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